Making a case for metformin

Contemporary Ob/Gyn

Volumn 48, Issue 3, 2003, Pages 69-80

  Kosasa, Thomas S ^a   Burns, John A ^b  

^a UNIVERSITY OF HAWAII   (United States)

^b School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77950089122     PISSN: 00903159     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum-free testos-terone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med. 1996;335:617-623.
2. Nestler JE, Bariascinf CO, Matt DW, et al. Suppression of serum insulin by diazoxide reduces serum testosterone levels in obese.
3. Chang RJ, Nakamura RM, Judd HL, et al. Insulin resistance in nonobese patients with polycystic ovarian disease. J Clin Endocrinol Metab. 1983;57:356-359.
4. Nestler JE, Jakubowicz DJ. Lean women with poly-cystic ovary syndrome respond to insulin reduction with decreases in ovarian P450cl7 alpha activity and serum androgens. J Clin Endocrinol Metab. 1997:82:4075-4079.
5. Bailey CJ, Turner RC. Metformin. N Engl J Med. 1996;334:574-579.
6. Velazquez EM, Mendoza S, Hamer T, et al. Metformin therapy in polycystic ovary syndrome reduces hyperinsu-linemia, insulin resistance, hyperandrogenemia, and sys-tolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647-654.
7. Velazquez E, Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syn-drome. Obstet Gynecol. 1997;90:392-395.
8. Crave JC, Fimbel S, Lejeune H, et al. Effects of diet and metformin administration on sex hormone-binding globulin, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab. 1995;80:2057-2062.
9. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997;82:524-530.
10. Acbay O, Gundogdu S. Can metformin reduce insulin resistance in polycystic ovary syndrome? Fertil Steril. 1996;65:946-949.
11. Homburg R. Should patients with polycystic ovary syndrome be treated with metformin? A note of cautious optimism. HumReprod. 2002;17:853-856.
12. Morin-Papunen LC, Koivunen RM, Ruokonen A. Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil Steril. 1998;69:691-696.
13. Nestler JE, Jakubowicz DJ, Evans WS, et al. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-1880.
14. Glueck CF, Wang P, Fontaine R, et al. Met-formin-induced resumption of normal menses in 39 of 43 (91%) previously amenorrhea women with the polycystic ovary syndrome. Metabolism. 1999;48:511-519.
15. Sarlis NJ, Weil SJ, Nelson LM. Administration of met- formin to a diabetic woman with extreme hyperandrogen-emia of nontumoral origin: management of infertility and prevention of inadvertent masculinization of a female fetus. J Clin Endocrinol Metab. 1999;84:1510-1512.
16. Kolodziejczyk B, Duleba AJ, Spaczynski RZ, et al. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syn-drome. Fertil Steril. 2000;73:1149-1154.
17. Seale FG, Robinson RD, Neal GS. Association of met-formin and pregnancy in the polycystic ovary syndrome. A report of three cases. J Reprod Med. 2000;45:507-510.
18. Moghetti P, Castello R, Negri C, et al. Metformin effects on clinical features, endocrine and metabolic pro-files, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebocontrolled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab. 2000;85:139-146.
19. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syn-drome who are resistant to clomiphene citrate alone. Fertil Steril. 2001;75:310-315.
20. Batukan C, Baysal B. Metformin improves ovulation and pregnancy rates in patients with polycystic ovary syn-drome. Arch Gynecol Obstet. 2001;265:124-127.
21. Ng EH, Wat NM, Ho PC. Effects of metformin on ovu-lation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a random-ized, double-blinded placebo-controlled trial. Hum Reprod. 2001;16:1625-1631.
22. Sturrock ND, Lannon B, Fay TN. Metformin does not enhance ovulation induction in clomiphene resistant poly-cystic ovary syndrome in clinical practice. Br J Clin Pharmacol. 2002;53:469-473.
23. De Leo V, la Marca A, Ditto A, et al. Effects of met-formin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. Fertil Steril. 1999:72:282-285.
24. Stadtmauer LA, Riehl RM, Toma SK, et ai. Metformin treatment of patients with polycystic ovarian syndrome undergoing IVF increases the number of mature oocytes, the fertilization rate and the number of embryos with changes in the levels of insulin-like growth factors. 1999;72:S12. Abstract nr 0-031.
25. Balen AH, Tan SL, MacDougall J, et al. Miscarriage rates following in vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensiti-zation with buserelin. Hum Reprod. 1993;8:959-964.
26. Homburg R, Armar NA, Eshel A, et al. Influence of. serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1988;297:1024-1026.
27. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility, and miscarriage. Lancet. 1990;336:1141-1144.
28. Sagle M, Bishop K, Ridley N, et al. Recurrent early miscarriage and polycystic ovaries. BMJ. 1988; 297:1027-1028.
29. Watson H, Kiddy DS, Hamilton-Fairley D, et al. Hypersecretion of luteinizing hormone and ovarian steroids in women with recurrent early miscarriage. Hum Reprod. 1993;8:829-833.
30. Gray RH, Wu LY. Subfertility and risk of spontaneous abortion. Am J Public Health. 2000;90:1452-1454.
31. Regan L, Braude PR, Trembath PL. Influence of past reproductive performance on risk of spontaneous abor-tion. BMJ. 1989;299:541-545.
32. Clifford K, Rai R, Watson H, et al. An informative pro-tocol for the investigation of recurrent miscarriage: pre-liminary experience of 500 consecutive cases. Hum Reprod. 1994;9:1328-1332.
33. Uddell HS, Sowden K, Farquhar CM. Recurrent mis-carriage: screening for polycystic ovaries and subsequent pregnancy outcome. Aust N 2 J Obstet Gynaecol. 1997;37:402-406.
34. Fedorcsak P, Storeng R, Dale PO, et al. Obesity is a risk factor for early pregnancy loss after IVF or ICSI. Acta Obstet Gynecol Scand. 2000;79:43-48.
35. Craig LB, Le RW, Kutteh WH. Increased prevalence of insulin resistance in women with a history of recurrent pregnancy loss. Fertil Steril. 2002;78:487-490.
36. Glueck CJ, Wang P, Fontaine RN, et ai. Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome. Metabolism. 1999:48:1589-1595.
37. Velazquez EM, Mendoza SG, Wang P, et al. Metformin therapy Is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein (a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. Metabolism. 1997:46:454-457.
38. Glueck CJ, Phillips H, Cameron D, et al. Metformin throughout pregnancy in women with polycystic ovary syndrome reduces first-trimester miscarriage from 45% to 5%. J Invest Med. 2000;48:188A.
39. Glueck CJ, Phillips H, Cameron D, et al. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. Fertil Steril. 2001;75:46-52.
40. Radon PA, McMahon MJ, Meyer WR. Impaired glu-cose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol. 1999;94:194-197.
41. Mikola M, Hiilesmaa V, Halttunen M, et al. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod. 2001;16:226-229.
42. Glueck CJ, Wang P, Kobayashi S, et al. Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovary syndrome. Fertil Steril. 2002;77:520-525.
43. Buchanan TA, Xiang AH, Peters RK, et al. Response of pancreatic beta-cells to improved insulin sensitivity in women at high risk for type 2 diabetes. Diabetes. 2000;49:782-788.
44. Sills ES, Perloe M, Palermo GD. Correction of hyperinsulinemia in oligo-ovulatory women with clomiphene-resistant polycystic ovary syndrome: a review of 18 therapeutic rationale and reproductive outcomes. Eur J Obstet Gynecol Reprod Biol. 2000;91:135-141.
45. Barbieri RL. Induction of ovulation in infertile women with hyperandrogenism and insulin resistance. Am J Obstet Gynecol. 2000;183:1412-1418.
46. Huckabee WE. Lactic acidosis. Am J Cardiol. 1963;12:663-666.
47. Lalau JD, Race JM. Lactic acidosis in metformin therapy. Drugs. 1999;58:55-60; discussion 75-82.
48. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137:25-33.
49. Nestler JE, Stovall D, Akhter N, et al. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome. Fertil Steril. 2002;77:209-215.